Compare Alcon AG (ALC) vs Global X FTSE Southeast Asia ETF (ASEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alcon AG vs Global X FTSE Southeast Asia ETF — how do they compare? Alcon AG trades at $74.19 (market cap $36.44B), while Global X FTSE Southeast Asia ETF trades at $21.47. The key difference: Alcon AG pays a 0.48% dividend while Global X FTSE Southeast Asia ETF pays none, and Global X FTSE Southeast Asia ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | ASEA | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.12 | $21.53 |
52-Week Low | $62.02 | $16.86 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ASEA trades at $21.53, up 1.41% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows uniform support and resistance at $21. Key financial ratios are unavailable, but a dividend of $0.41 is scheduled for July 2026. Recent business developments and earnings data are not provided, limiting fundamental assessment.
The outlook is cautiously optimistic due to strong technical momentum, though the absence of current financial metrics and news increases uncertainty. Investment opportunity hinges on upcoming financial disclosures, while risks include data gaps and market volatility. Investors should await earnings reports for clearer valuation insights.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Global X FTSE Southeast Asia ETF
ASEA tracks the performance of the largest companies in Southeast Asia. It provides exposure to key emerging markets including Singapore, Indonesia, Thailand, and Malaysia, with a heavy focus on financials like DBS Group and Bank Central Asia.
Read more on ASEA →
